Insmed Incorporated
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company founded in 1988 and headquartered in Bridgewater, New Jersey, focuses on rare diseases with investigational and approved therapies in pulmonary, inflammatory, and other serious conditions; its approved products include ARIKAYCE (amikacin liposome inhalation suspension) for Mycobacterium avium complex lung disease in adults with limited treatment options and BRINSUPRI (brensocatib), a first-in-class neutrophil elastase inhibitor for non-cystic fibrosis bronchiectasis; the company advances a pipeline encompassing TPIP for pulmonary arterial hypertension, INS1201, and preclinical programs in gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, serving patients primarily through clinical trials and commercial launches targeting chronic lung diseases. Insmed operates 9 corporate offices and 4 global research sites across the United States, Europe, Japan, and other regions, with over 1,500 employees as of mid-2025. Recent developments include FDA approval of BRINSUPRI in 2025 and its subsequent European Union approval, topline results from the Phase 2b pulmonary arterial hypertension study and Phase 3 ASPEN study in 2024-2025, the opening of a new research lab in Cambridge, UK, a proposed $650 million public offering of common stock in June 2025, raised full-year 2025 ARIKAYCE revenue guidance to $420-430 million, and repeated recognition as the No. 1 biopharma employer by Science magazine.
Company News
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Insmed to Present at September 2026 Investor Conferences
Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal
Alger Mid Cap 40 ETF Q2 2026 Portfolio Review
BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
Invesco Discovery Mid Cap Growth Fund Q2 2026 Portfolio Performance
Biotech Is Booming, But These 2 Stocks Missed the Memo
Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake
Insmed Q2 Earnings Call Highlights
Insmed Incorporated (INSM) Q2 2026 Earnings Call Transcript
Insmed (INSM) Reports Q2 Earnings: What Key Metrics Have to Say
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
Insmed, Inc. $INSM Stock Holdings Reduced by Bank of Nova Scotia
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026
Andra AP fonden Buys 41,670 Shares of Insmed, Inc. $INSM
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday